In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
about
Oral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain TraumaInsulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats.Cerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [11C]PiB Uptake Distinguish among and between Neurodegenerative Disorders and Aging.The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.Insulin degludec + liraglutide: a complementary combination.Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.The neuronal insulin receptor in its environment.Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.Obesity as a risk factor for Alzheimer's disease: weighing the evidence.Fenugreek Compound (N55) Lowers Plasma Glucose through the Enhancement of Response of Physiological Glucagon-like peptide-1.Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells.Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus.No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide enhances hippocampal long-term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation.Tackling dipeptidyl peptidase IV in neurological disorders.The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice.Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review.Sweet Mitochondria: A Shortcut to Alzheimer's Disease.
P2860
Q28591252-2548592C-7748-4324-99B5-42D89981D672Q33628048-4C52421F-0507-4DE3-8F0B-4C8F139D08A7Q33731321-BEFE45F2-74EF-4DF1-8745-E4DC6B5691EAQ33800802-E233D622-E3C9-45AA-8E7A-2971FF79B18FQ37421211-878967CE-904F-4AA5-A86B-57AC5470A18DQ37578233-95E3528D-6F33-4771-9258-DDCE1ED5DAB0Q37637480-98D8AD66-E085-4581-81E6-796B92FC773BQ38758318-758DEFFD-D508-4FCD-A986-8D5B3D44E36AQ38916256-576D02A7-CA59-41C2-922E-2EFFC35E4D79Q38974881-6EAEEAFA-DEA9-4FF9-9EED-AAA5649587BBQ39021127-BA73C1D0-551A-4666-8032-96F725BE31D3Q39042377-53560A27-41C4-4F1D-A7A5-967B59A6FC70Q39270980-5EDC9A34-7141-4764-A40B-EDD671546589Q41986529-4EC04078-0D71-4BA3-B83B-CA06045AA61FQ42363737-7D7CC637-C7F9-4B05-B2A8-FE74DBE778EDQ47107585-A52E3EF5-2CB2-4F72-B322-CA68905AA5CAQ47110521-9437F9CC-4EA2-4D0A-8A51-596A4F07D958Q47266756-6619F999-D070-4770-8C20-ABB472558F07Q47785459-F4CFCEBB-CDF6-4B14-BC3C-C90B2458E05BQ47915902-410CD549-C3BB-4747-9143-52C2DC5A7C98Q49940117-3D0BDCD5-6E2C-4BE6-AF1A-E32A257D0BA4Q50050282-DB754F45-73D8-4C20-A967-BEE4BE77F912Q50446239-423ED4CC-BB95-4E49-A77A-3696BD99BE4FQ53685113-499AC5BC-AC57-44D2-A409-7BD34A504C75Q55306046-2005B4C2-1052-47DD-9FAE-995E007BD4C7
P2860
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
In Alzheimer's Disease, 6-Mont ...... , Double-Blind Clinical Trial.
@en
type
label
In Alzheimer's Disease, 6-Mont ...... , Double-Blind Clinical Trial.
@en
prefLabel
In Alzheimer's Disease, 6-Mont ...... , Double-Blind Clinical Trial.
@en
P2093
P2860
P356
P1476
In Alzheimer's Disease, 6-Mont ...... , Double-Blind Clinical Trial.
@en
P2093
Anders Rodell
Anna Schacht
Arne Møller
Birgitte Brock
Hanne Gottrup
Hans Brændgaard
Jørgen Rungby
Lærke Egefjord
Michael Gejl
P2860
P356
10.3389/FNAGI.2016.00108
P577
2016-05-24T00:00:00Z